Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...

Bladder cancer patients who run out of options often face a grim choice: life-altering surgery to remove the bladder, or living with a disease that might kill them if it spreads to the rest of the ...

Natera (NTRA) announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer. The ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

A new drug delivery system has shown remarkable success in treating a common form of bladder cancer that had stopped ...

Pro Football Hall of Famer Deion Sanders is making headlines after revealing he was diagnosed with an aggressive form of bladder cancer earlier this year.

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...